

Second Annual Conference of The International Society for the Study of Drug Policy

Scientific Programme

Thursday April 3, 2008

9.00 **Opening Session**

Fátima Trigueiros, IDT, I.P.
Roland Simon, EMCDDA
Peter Reuter, ISSDP President
Henri Bergeron, Conference Chair

9:30 **Plenary Session/Auditorium**

Chair: Peter Reuter (University of Maryland, USA)

Drug Policy in World Historical Perspective: The Five Stages of Regulation

David Courtwright (University of North Florida, USA)

10. 15 **Parallel sessions A&B**

1 a) Policy **Evaluation I**

Chair: Henri Bergeron (CSO-CNRS – Sciences Po Paris, France)

The development of an Australian drug policy index

Speaker: *Alison Ritter* (Drug Policy Modeling Program, University of New South Wales, Australia)

Cocaine and the Caribbean: evaluating UK and Dutch counter-drugs policies

Speaker: *Martin Elvins* (University of Dundee, U.K.)

Regulating khat-Dilemmas and opportunities

Speaker: *Axel Klein* (University of Kent, U.K.)

Discussant: Casimiro Balsa (Faculdade de Ciências Sociais e Humanas, Universidade Nova de Lisboa, Portugal)

1 b) Policy **Evaluation II**

Chair: Maria Moreira (EMCDDA, Portugal)

Evaluating Danish cannabis policy change

Speaker: *Kim Møller* (Center for Alcohol and Drug Research, Denmark)

The cannabis classification debate in the UK: full of sound and fury, signifying nothing.

Speaker: *Charlie Lloyd* (Joseph Rowntree Foundation, U.K.)

The baby, the bathwater and the legacy of normalization: understanding young people's drug use

Fiona Measham (Lancaster University, UK)

Discussant: Fernando Mendes (IDT, I.P., Portugal)

11.45 **Coffee – break**

12:00 **Parallel sessions**

2 a) **Modeling drug treatment**

Chair: Julian Vicente (EMCDDA, Portugal)

The role of medicine assisted drug treatment within Nordic drug and health policy - a discussion

Speakers: *Pia Rosenqvist* (Nordic Council on Alcohol and Drugs, Finland) and *Astrid Skretting* (SIRUS, Norway)

The dynamics of marijuana treatment

Speaker: *Beau Kilmer* (Drug Policy Research Center, RAND, USA)

Is it in medical centers' self-interest to provide drug dependence treatment? : a cost-consequence analysis in a national health care system

Speaker: *Keith Humphreys* (Stanford University, USA)

Discussant: Ambros Uchtenhagen (Research Institute for Public Health and Addiction, Switzerland)

2b) **Managing drug-involved offenders**

Chair: Miguel Vasconcelos (IDT, I.P., Portugal)

Drug Testing and Sanctions in Hawaii: Preliminary Results from Project HOPE

Speaker: *Mark Kleiman* (UCLA, USA)

The Beginning of HOPE

Steven Alm (1st Judicial Circuit, Hawaii, USA)

Behavioral Economics and Parole Supervision

Angela Hawken (Pepperdine University, USA) [paper to be presented by Mark Kleiman]

Discussant: Nicola Singleton (UK Drug Policy Commission, UK)

1:30 pm **Lunch**

2.30 pm **Plenary Session**

Chair: Michael Farrell (National Addiction Center, UK)

The adverse health effects of cannabis and their implications for policy

Wayne Hall (University of Queensland, Australia)

3.15 pm **Parallel sessions**

3a) **Governance and policy formation**

Chair: Laurent Laniel (EMCDDA, Portugal)

An ecological system view of United States illicit drugs policy and the role of public health

Yvonne M. Terry-McElrath (University of Michigan, USA)

Malaysian illicit drug policy: top down multi agency governance or bottom up multi level governance

Vicknasingam Balasingam Kasinather (Centre For Drug Research, University Sains Malaysia, Malaysia)

Harm-reduction measures, police activity and incidence of heroin use: the Zurich experience

Carlos Nordt (Psychiatric University Hospital, Zurich, Switzerland)

Discussant: Suzanne McGregor (London School of Hygiene and Tropical Medicine, UK)

3b) **Formal models, policy and inertia**

Chair: Lucas Wiessing (EMCDDA, Portugal)

Optimal use and harm reduction in drug epidemics

Dagmar Wallner and Gernot Tragler (Technical University of Vienna, Austria)

A system dynamic model of Australian opioid pharmacotherapy maintenance treatment

Jenny Chalmers (Drug Policy Modeling Program, University of New South Wales, Australia)

Understanding inertia: inherent limitations on evaluating "upstream" drug control interventions

Jonathan P. Caulkins and Irmgard Zeiler (Carnegie-Mellon University, USA)

Discussant: Peter Reuter (University of Maryland, USA)

4.45 pm **Coffee-break**

5.00 pm **Annual meeting of the ISSDP**

6.00 pm **End of the Day**

7.00 pm **Reception by the Portuguese hosts**

"Museu da Cidade" – The City Museum

Friday April 4, 2008

9.00 **Plenary Session**

Chair: Sandeep Chawla (UNODC, Austria)

From fundamentalism to technocracy – learning from Swiss policy failures in the fight against drug abuse.

Sandro Cattacin (University of Geneva, Switzerland)

9.45 **Parallel sessions A&B**

4a) **Drug market dynamics I**

Chair: Kevin Sabet (NDRI, USA)

Price variation in the UK market for cocaine and heroin

Kevin Marsh (Matrix Research and Consulting, UK)

The "flexible" response of cannabis markets to enforcement/interdiction policy: An international review of market transformations and elasticities

Bruce D. Johnson (NDRI, USA)

Modelling cocaine and heroin market in the era of globalization and drug reduction policies

Cláudia Costa Storti (EMCDDA, Portugal)

Discussant: Benedikt Fischer (University of Victoria, Canada)

4b) Drug market dynamics II

Chair: Chloé Carpentier (EMCDDA, Portugal)

A few buds for a few bucks? Youth involvement in the marijuana cultivation industry

Martin Bouchard (Simon Fraser University, Canada)

High-dose buprenorphine: A shock on the supply-side market of the heroin in France

Christian Ben Lakhdar (OFDT, France)

A search-theoretic model of the retail market for illicit drugs

Rosalie Liccardo Pacula (Drug Policy Research Center, RAND, USA)

Discussant: Mark Kleiman (UCLA, USA)

11.15 **Coffee**

11.30 **Parallel sessions A&B**

5 a) **Costs and Expenditures**

Chair: Fátima Trigueiros (IDT, I.P., Portugal)

Public expenditures on drug policy

Jiri Vopravi (National Statistical Office, The Czech Republic)

Proposal of a new standardized data collection form to estimate drug-related public expenditures in the European Union

Luis Prieto (EMCDDA, Portugal)

An alternative framework for measuring the economic cost of drug abuse

Rosalie Pacula (Drug Policy Research Center, RAND, USA)

Discussant: Harold Pollack (University of Chicago, USA)

5b) **Testing and Incarceration**

Chair: Jorge Negreiros (Faculdade de Psicologia e Ciências da Educação, Universidade do Porto, Portugal)

Drug testing in Schools and Workplaces: Policy implications and considerations of punitive deterrence and/or prevention measures

Ann M. Roche (National Center for Education and Training, Australia)

Drug testing in schools – evaluating a high school’s drug testing program: Implications for future school drug testing policies

Howard Taras (University of California, San Diego, USA)

Alternatives to what? The effects of alternatives to prison for drug-related offenders

Alex Stevens (University of Kent, UK)

Drugs and prisons in Portugal: inmates and directors, agreements and disagreements

Anália Cardoso Torres (Instituto Superior de Ciências do Trabalho e da Empresa, Portugal)

Discussant: Brendan Hughes (EMCDDA, Portugal)

1.30 pm **Lunch**

2.30 pm **Plenary Session**

Chair: Margaret Hamilton (Australian National Council on Drugs)

Maintaining Addicts on Heroin: Making Sense out of Apparent Nonsense

John Strang (National Addiction Center, UK)

3.15 pm **Parallel sessions**

6 a) **Drug problem – use patterns and consequences**

Chair: Frank Zobel (EMCDDA, Portugal)

Youth, contemporary drug policy, social control, the dance scene and social control

Geoffrey Hunt (Institute for Scientific Analysis, USA)

Using microsimulation modeling to capture heterogeneity in marijuana use

Susan M. Paddock (Drug Policy Research Center, RAND, USA)

Biography of an epidemic: The outbreak (and decline) of fentanyl overdose deaths in Chicago

Harold A. Pollack, Greg Scott and Sandra D. Thomas (University of Chicago, USA)

Discussant: Jean-Michel Costes (OFDT, France)

6b) **Policy change: analysis and models**

Chair: Henri Bergeron (CSO-CNRS – Sciences Po Paris, France)

Complementary or contradictory drug policies

Michael Jourdan (Center for Alcohol and Drug Research, Denmark)

Risk, Security and the ‘Criminalization’ of British Drug Policy

Robert Ralphs and Lisa Williams (University of Manchester, UK)

The Dutch drug policy: an overview and an exploratory evaluation

M.M.J. van Ooyen-Houben (Ministry of Justice, Netherlands)

Variations in Effective Illegality and Their Effects Upon The World Opiate Market

Letizia Paoli, (Katholik University of Leuven, Belgium)

Discussant: Robin Room (Turning Point, Australia)

4.45 pm **Coffee break**

5.00 pm **Final address**